Health Care • Biotechnology: Pharmaceutical Preparations
$0.93 ▲ +0.05
(+5.09%)
MKT CAP: $13.8M • VOL: 148.7K
52W L $1 52W H $2
ROARABLE / RQD
D- • 40/100
PIOTROSKI
3 / 9
BFRI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $41.7M | $37.3M | $34.1M |
| YoY Revenue Growth % | +11.7% | +9.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.3M | -$17.2M | -$22.7M |
| Operating Margin % | -27.2% | -46.1% | -66.6% |
| Net Income (GAAP) | -$10.5M | -$17.8M | -$20.1M |
| EBITDA (Normalized) | -$11.3M | -$17.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.4M | -$10.3M | -$24.9M |
| Capital Expenditures (CapEx) | $2.0K | $10.0K | — |
| Free Cash Flow (FCF) | -$13.4M | -$10.3M | -$24.9M |
| FCF Margin % | -32.0% | -27.5% | -73.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.4M | $5.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $10.5M | $4.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BFRI.